概括
基于血液的生物标志物有助于诊断阿尔茨海默氏症,但PET和CSF测试可能不同意. 整合PET,CSF和血数据的新模型为粉样蛋白阳性评估提供了更高的准确性.
科学领域:
- 神经学 神经学
- 生物标志物发现发现
- 医学诊断 医学诊断 医学诊断
背景情况:
- 基于血液的生物标志物是阿尔茨海默病 (AD) 中粉样蛋白确认的新兴工具.
- 目前的性能评估通常依赖于单个比较器,忽视了粉样蛋白正子辐射断层扫描 (PET) 和脑脊液 (CSF) 测定之间的不一致性.
- 这种不一致凸显了对综合分析方法的需求.
研究的目的:
- 开发和验证贝叶斯潜伏类模型,整合PET,CSF和血生物标志物,以估计粉样蛋白阳性.
- 评估PET-CSF条件依赖,时间间隔和CSF切断对诊断概率的影响.
- 探索模式对概率报告作为一种解释生物标志物结果的方法,而不优先考虑参考测试.
主要方法:
- 对阿尔茨海默病神经成像计划 (ADNI) 数据的截面二次分析 (n=320).
- 贝叶斯潜伏类模型包含PET,CSF (Aβ42/40或%p-tau217) 和等离子生物标志物.
- 对PET-CSF依赖性,时间差距 (≤7,8-30,>30天) 和CSF切割点进行了敏感性分析.
主要成果:
- 一致的PET+/CSF+和PET-/CSF-模式对应于粉样蛋白阳性的高和低概率,分别.
- 不一致的PET/CSF模式产生了中间概率,通过血生物标志物层进行细化.
- 即使在7天内 (12%),也观察到PET-CSF异调.
- 脑脊Aβ42覆盖率分析显示了类似的诊断梯度.
结论:
- 使用PET,CSF和等离子体生物标记物的综合贝叶斯模型提供了粉样蛋白阳性的细微概率.
- 模式对概率报告可以提高对阿尔茨海默病诊断中的复杂生物标志物数据的解释.
- 这些发现强调了在临床实践中考虑生物标志物不一致性和分析假设的重要性.
相关概念视频
Amyloid Fibrils
12.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.0K
Amyloid Fibrils
6.4K
6.4K
Cerebrospinal Fluid
6.0K
Cerebrospinal fluid (CSF) is a colorless liquid that flows around the brain and the spinal cord, playing a vital role in the protection, support, and overall function of the central nervous system (CNS). CSF production, circulation, and absorption are tightly regulated processes essential for the brain and spinal cord to function properly.
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
6.0K
Probability Laws
44.4K
Overview
44.4K
Alzheimer's Disease: Treatment
963
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
963
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K


